VEGFA and neoplasm: The results showed that ECOG-PS score, fruquintinib or regorafenib targeted therapy and previous anti-VEGF therapy were independent prognostic factors affecting PFS, and patients who did not receive anti-VEGF therapy in previous anti-tumor therapy may have longer PFS than those who received anti-VEGF therapy.